Many years before the term “molecular targeting” was popularized in cancer therapeutics, the epidermal growth factor (EGF) and its receptor (EGFR or ErbB-1 or HER1) were recognized as important molecular regulators of cellular growth and differentiation [(1][1] [, 2)][2] .
No takes yet. Share an insight, caveat, or question.
Harari et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: